Advanced Enzyme Technologies Ltd has announced a special window facility for shareholders holding physical shares to facilitate transfer and dematerialization processes. The company made this announcement on February 10, 2026, through newspaper publications and regulatory filings.

Regulatory Compliance and Communication

The company issued this intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Advanced Enzyme Technologies communicated this development to both major stock exchanges where its shares are listed.

Publication and Notification Process

The special window announcement was published in two prominent newspapers on February 10, 2026:

• Free Press Journal
• Navshakti

This publication serves to inform members holding physical shares about the availability of the special facility for transfer and dematerialization of their shareholdings.

Company Information

Advanced Enzyme Technologies Ltd operates from its registered office located at Sun Magnetics, 'A' wing, 5th Floor, LIC Service Road, Louiswadi, Thane (W)-400 604, India. The company maintains regular communication channels with shareholders through multiple contact methods including telephone, fax, and email services.

Documentation and Records

The company has enclosed copies of the newspaper publications with its regulatory filing, ensuring complete documentation of the public notice. Company Secretary and Head-Legal Sanjay Basantani signed the communication, which was digitally authenticated on February 10, 2026, at 14:38:10 +05'30'.

This initiative demonstrates the company's commitment to facilitating shareholder services and ensuring compliance with regulatory requirements for share transfer and dematerialization processes.

Advanced enzyme tech has released the complete transcript of its conference call held on February 4, 2026, discussing Q3FY26 unaudited financial results. The comprehensive document provides detailed insights into the company's financial performance and management commentary on market conditions.

Financial Performance Overview

The company reported mixed performance for the quarter, with revenue reaching INR 1,719 million, reflecting 2% year-on-year growth but a 7% decline compared to the previous quarter. On a nine-month basis, revenue grew by 15%.

Segment-wise Performance

Human Healthcare, the company's largest segment contributing 56% of total revenue, recorded INR 962 million in Q3 FY26, showing a 6% year-on-year decline. The management attributed this decline to lower sales in Pharma, API, and Nutrition businesses across both domestic and international markets.

Animal Healthcare demonstrated strong performance with revenue of INR 241 million, delivering 22% year-on-year growth and accounting for 14% of total revenue. The Bioprocessing segment recorded 13% year-on-year growth, primarily driven by robust performance in the food business, which grew 16% year-on-year.

Market Challenges and Outlook

During the conference call, management discussed the impact of global market disruptions due to U.S. tariffs. Chairperson Vasant Rathi noted that reciprocal tariffs have been reduced from 25% to 18%, and the additional penal levy of 25% imposed on India for buying Russian oil has been dropped.

The company maintains its focus on operational excellence and remains optimistic about growth prospects. Management indicated seeing increased inquiries and interest, particularly in the U.S. market, which should reflect in future performance.

Regulatory Compliance

The transcript release follows the company's regulatory obligations under SEBI LODR Regulations 2015. The document was communicated to both BSE Limited and National Stock Exchange of India Limited on February 7, 2026, and has been uploaded to the company's website for stakeholder access.

Future Initiatives

Management highlighted plans for a new R&D center in Nashik, expected to be operational by the end of the second quarter of the coming year. The facility will focus on strain development, protein engineering, and fermentation, aimed at accelerating product development and expanding market opportunities.